Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 4/2010

01-11-2010 | Letter to the Editor

A case of anaplastic large cell lymphoma, ALK positive, primary presented in the skin and relapsed with systemic involvement and leukocytosis after years of follow-up period

Authors: Masataka Hosoi, Motoshi Ichikawa, Yoichi Imai, Mineo Kurokawa

Published in: International Journal of Hematology | Issue 4/2010

Login to get access

Excerpt

Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is one disease form of primary cutaneous T cell lymphoma (CTCL) that presents diffuse infiltration of large CD30 positive tumor cells. Its clinical course is usually favorable, with a 10-year disease-related survival of approximately 90% [1]. Unlike systemic anaplastic large cell lymphoma (ALCL), C-ALCL usually does not have translocations involving the anaplastic lymphoma kinase (ALK) gene. We report a case of ALK positive C-ALCL previously reported at the time of diagnosis [2] who developed systemic relapse with leukocytosis after years of the clinical course. …
Literature
1.
Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, Meijer CJ, Willemze R. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653–61.PubMed
2.
Sasaki K, Sugaya M, Fujita H, Takeuchi K, Torii H, Asahina A, Tamaki K. A case of primary cutaneous anaplastic large cell lymphoma with variant anaplastic lymphoma kinase translocation. Br J Dermatol. 2004;150:1202–7.CrossRefPubMed
3.
Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia. 2000;14:1533–59.CrossRefPubMed
4.
Wood GS, Hardman DL, Boni R, Dummer R, Kim YH, Smoller BR, Takeshita M, Kikuchi M, Burg G. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin’s disease. Blood. 1996;88:1765–70.PubMed
5.
DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood. 1996;87:3437–41.PubMed
6.
Woo DK, Jones CR, Vanoli-Storz MN, Kohler S, Reddy S, Advani R, Hoppe RT, Kim YH. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol. 2009;145:667–74.CrossRefPubMed
7.
Beylot-Barry M, Lamant L, Vergier B, de Muret A, Fraitag S, Delord B, Dubus P, Vaillant L, Delaunay M, MacGrogan G, et al. Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. Am J Pathol. 1996;149:483–92.
Metadata
Title
A case of anaplastic large cell lymphoma, ALK positive, primary presented in the skin and relapsed with systemic involvement and leukocytosis after years of follow-up period
Authors
Masataka Hosoi
Motoshi Ichikawa
Yoichi Imai
Mineo Kurokawa
Publication date
01-11-2010
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0708-4

Other articles of this Issue 4/2010

International Journal of Hematology 4/2010 Go to the issue

Case Report

Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib

Original Article

Establishment of an HS23 stromal cell-dependent myeloma cell line: fibronectin and IL-6 are critical

Original Article

Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma

Letter to the Editor

AA amyloidosis associated with macroglobulinemia

Letter to the Editor

Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions

Original Article

C/EBPβ and CHOP participate in Tanshinone IIA-induced differentiation and apoptosis of acute promyelocytic leukemia cells in vitro
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits